Clinical Trial Update: Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 trial in pediatric patients with moderate to severe atopic dermatitis assessed the response and safety of 0.03% tacrolimus ointment. The study sponsor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Tacrolimus Ointment 0.03% (Tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Dermatitis, Atopic | Phase 3 | Status: COMPLETED